Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Acta Anaesthesiol Scand ; 59(2): 197-204, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25476454

RESUMO

BACKGROUND: International guidelines recommend noradrenaline (NA) as the vasopressor of choice to treat septic shock. The aim of this study was to determine the best way to infuse patients with NA. METHODS: The in vitro study was designed to measure NA concentration at the end of each studied assembly line. Three infusion systems used the double pump method and three single pumps, which differed as regards NA concentrations (0,2 - 0,5 - 1 mg/h), dead space volume of the devices and the use of saline. Infusion systems were compared according to the time necessary to reach an NA mass flow rate steady-state plateau after the onset of infusion or after a flow change. RESULTS: Times were significantly different between the six methods for infusing NA. The system using the double syringe method with a standard extension set was the longest to reach the steady state after the onset of infusion [40.00 min (19.57 - 49.22)]. The steady-state plateau was obtained most rapidly with the double-syringe pump systems using very low dead-space volume extension sets and single-syringe pump systems containing diluted noradrenaline at the beginning of NA infusion. CONCLUSION: A combination of a low dead-space volume extension set and a double pump method with a constant saline flow rate at 5 ml/h might be the solution to provide the most reliable NA infusion delivery.


Assuntos
Sistemas de Liberação de Medicamentos/instrumentação , Bombas de Infusão , Norepinefrina/administração & dosagem , Vasoconstritores/administração & dosagem , Desenho de Equipamento , Humanos , Técnicas In Vitro , Infusões Intravenosas/instrumentação , Seringas , Fatores de Tempo
4.
Monaldi Arch Chest Dis ; 49(2): 131-7, 1994 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8049697

RESUMO

Between January 1989 and February 1993, 52 patients were evaluated at Niguarda Hospital for lung or heart and lung transplantation. Of the 35 that entered the waiting list, a total of 19 were transplanted (14 at other institutes before our surgical programme became operative, and 5 at our hospital). Recipient selection and evaluation criteria, and timing of transplantation in the different diseases are discussed.


Assuntos
Cardiopatias/cirurgia , Transplante de Pulmão , Doenças Respiratórias/cirurgia , Contraindicações , Feminino , Cardiopatias/diagnóstico , Cardiopatias/psicologia , Transplante de Coração-Pulmão/métodos , Hospitais Urbanos , Humanos , Itália , Transplante de Pulmão/métodos , Masculino , Complicações Pós-Operatórias/prevenção & controle , Doenças Respiratórias/diagnóstico , Doenças Respiratórias/psicologia , Fatores de Tempo , Listas de Espera
6.
Ital J Neurol Sci ; 11(2): 163-9, 1990 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-2163369

RESUMO

Multiple cerebral tuberculomas are now very rare. We report the case of a young man with an 8-month history of headache, febricula and abscess of the left tibiotarsal joint, which was found to contain mycobacterium tuberculosis. Chest X-rays revealed miliariform dissemination to both lungs while CT and MR brain scans revealed numerous small nodules, especially in the posterior cranial fossa. Despite anti-tuberculosis therapy the patient developed a right pyramidal hemisyndrome and intracranial hypertension. The inclusion of rifabutin in the treatment schedule was followed by rapid improvement and a year later the patient was in good health and free from cerebral and pulmonary lesions. The interest of the case lies in the multiplicity of sites of the TB process in a non immunodepressed patient, the dissemination to the CNS without meningeal involvement, the resistance to standard antimycobacterials and the swift response to rifabutin.


Assuntos
Antituberculosos/uso terapêutico , Encefalopatias/etiologia , Imageamento por Ressonância Magnética , Rifamicinas/uso terapêutico , Tuberculoma/diagnóstico , Adulto , Encefalopatias/diagnóstico , Encefalopatias/tratamento farmacológico , Humanos , Masculino , Rifabutina , Tuberculoma/tratamento farmacológico
7.
Clin Ther ; 12(2): 105-17, 1990.
Artigo em Inglês | MEDLINE | ID: mdl-2112984

RESUMO

Patients who were cigarette smokers suffering exacerbations of chronic bronchitis were examined in eight outpatient clinics in five regions of Italy, three from the South (Campania, 82 patients; Sicily, 82 patients; and Puglia, 29 patients) and two from North (Lombardy, 33 patients; and Liguria, 50 patients). Haemophilus influenzae was the most frequently isolated bacterium in the patients' sputum (in 30% of the total group), followed by Streptococcus pneumoniae (in 20%), Staphylococcus aureus (in 25%), and Branhamella catarrhalis (in 7%). H. influenzae was the most common bacterium in the South (in 37%) and S aureus in the North (in 13%). Smoking index scores (number of cigarettes smoked daily x years of smoking) were 827 in patients in whom H influenzae was isolated; 691 in patients with S aureus; 599 in patients with S pneumoniae; 542 in patients with B catarrhalis; and 446 in patients in whom no isolates were found. Pulmonary function was most severely decreased in patients positive for H influenzae and S aureus. The results indicate an association between heavy cigarette smoking and lower respiratory tract infections that is influenced by regional differences.


Assuntos
Bronquite/microbiologia , Fumar/efeitos adversos , Bronquite/etiologia , Doença Crônica , Resistência Microbiana a Medicamentos , Haemophilus influenzae/efeitos dos fármacos , Humanos , Itália , Moraxella catarrhalis/efeitos dos fármacos , Estudos Multicêntricos como Assunto , Staphylococcus aureus/efeitos dos fármacos , Streptococcus pneumoniae/efeitos dos fármacos
8.
J Infect ; 18(2): 151-65, 1989 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-2540243

RESUMO

Cryptococcosis and aspergillosis in immunocompromised patients are extremely difficult clinical conditions to manage and treatment with available antifungal drugs often fails. Itraconazole, R-51211, Janssen Pharmaceutica, a new orally absorbed triazole, is a possible alternative drug which is potentially effective and nontoxic. Preliminary experience with 28 patients, eight with cryptococcosis and 20 with aspergillosis, is reported. Of these patients, 16 were immunocompromised (seven with the acquired immune-deficiency syndrome (AIDS), five heart transplant recipients and four with leukaemia or lymphoma). Overall, results of treatment were good (18 in remission, four markedly improved, four moderately improved and two failed). Prevention of relapses of cryptococcosis was obtained in all patients with AIDS on long-term itraconazole monotherapy (3 mg/kg). Treatment of invasive aspergillosis required a higher dosage (about 5 mg/kg) and prolonged administration. Besides its efficacy this antifungal agent allowed outpatient management.


Assuntos
Antifúngicos/uso terapêutico , Aspergilose/tratamento farmacológico , Criptococose/tratamento farmacológico , Cetoconazol/análogos & derivados , Síndrome da Imunodeficiência Adquirida/complicações , Adulto , Anfotericina B/uso terapêutico , Aspergilose/diagnóstico , Criptococose/diagnóstico , Doença , Transplante de Coração , Humanos , Terapia de Imunossupressão , Itraconazol , Cetoconazol/uso terapêutico , Masculino , Neoplasias/complicações , Infecções Oportunistas/tratamento farmacológico
9.
Semin Oncol ; 15(6 Suppl 7): 20-5, 1988 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-2851172

RESUMO

Cis-Dichlorodiammine platinum (II) (cis-DDP) was demonstrated to be a potentiator of radiation therapy (RT) in experimental tumor models and in cultured cells. To assess the effectiveness of a combined modality treatment including RT and a weekly low-dose administration of cis-DDP, from January 1986 to June 1987, 95 patients with unresectable locally advanced non-small cell carcinoma of the lung (stage IIIa, b) were randomized for study. Fifty patients received RT alone at doses of 50 Gy; 45 patients received the same RT plus cis-DDP 15 mg/m2 IV weekly. An overall response rate of 50% and 64% was observed in the RT and RT + cis-DDP group, respectively. No statistically significant differences were detected with regard to median survival time (11 months for RT v 16 months for RT + cis-DDP) and progression-free interval (7 months in the RT arm v 9 months in the RT + cis-DDP arm), but the patterns of the first failure appeared to be affected by treatment. In fact, a lower number of intrathoracic relapses was observed in the RT + cis-DDP arm (12 in the RT + cis-DDP v 23 in the RT arm). Toxicity was mild and the feasibility of this schedule must be remarked. A better local control of disease can be obtained using cis-DDP as a radiation potentiator, but the true influence of this combined modality treatment on the length of survival, and the optimal cis-DDP timing and dosage are still to be evaluated in further clinical trials.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/terapia , Cisplatino/administração & dosagem , Neoplasias Pulmonares/terapia , Terapia Combinada , Humanos , Dosagem Radioterapêutica , Distribuição Aleatória
10.
Tumori ; 73(6): 623-5, 1987 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-3433370

RESUMO

The goal of this pilot study was to verify the efficacy of the association of cisplatin plus radiotherapy in the treatment of lung cancer. Thirty-seven consecutive patients entered the study. They were treated with radiotherapy (four weekly doses of 2.5 Gy for a total of 50 Gy) and cis-platin once weekly (12 mg/m2). Partial remission was obtained in 15 patients, and 1 patient had a complete remission. Three patients previously inoperable underwent surgical treatment. The actuarial survival curve of the 29 evaluable patients showed a mean survival of 8.5 months. The mean survival of the latter is not evaluable because half of the patients are still alive after 12 to 30 months. No hematologic or renal toxicity was observed with the above schedule.


Assuntos
Cisplatino/uso terapêutico , Neoplasias Pulmonares/terapia , Adulto , Idoso , Terapia Combinada , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Masculino , Pessoa de Meia-Idade
12.
Int J Clin Pharmacol Ther Toxicol ; 25(4): 229-32, 1987 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-3583473

RESUMO

The analgesic effect of salmon calcitonin (Calcitonina-Sandoz) was evaluated in an open study of thirty-four patients with bone metastases of a lung cancer. Two different administration protocols were used: eighteen subjects received sCT 400 IU/day for three consecutive days, while the remaining sixteen were given sCT 200 IU/day for six consecutive days. In both protocols salmon calcitonin was diluted in saline and infused intravenously in one hour. Bone, visceral and neuritic pain were evaluated by means of Huskisson's visual analog scale and Keele's pain scale. The analgesic efficacy of salmon calcitonin was also evaluated on the basis of daily consumption of analgesic drugs. Salmon calcitonin proved of extreme efficacy in the treatment of intractable pain from advanced malignancy. A higher and earlier analgesic activity was observed with sCT at the 400 IU daily dosage.


Assuntos
Neoplasias Ósseas/secundário , Calcitonina/uso terapêutico , Dor Intratável/tratamento farmacológico , Neoplasias Ósseas/fisiopatologia , Calcitonina/administração & dosagem , Esquema de Medicação , Feminino , Humanos , Neoplasias Pulmonares/fisiopatologia , Masculino , Pessoa de Meia-Idade , Dor Intratável/etiologia
14.
G Ital Cardiol ; 10(3): 309-15, 1980.
Artigo em Italiano | MEDLINE | ID: mdl-7372047

RESUMO

Svanborg (1961) found normal pulmonary artery mean pressures in eleven patients with stage II sarcoidosis. By contrast Gluskowski et al. (1978) have shown few abnormally high values in the same condition. We have not found published haemodynamic data concerning stage O sarcoidosis. Thus we have performed right haemodynamic study (by Swan-Ganz catheters) on 19 patients with hystologically proven sarcoidosis (8 stage III, 6 stage II, 3 stage I and 2 stage 0). 13 of them underwent also haemodynamic study during exercise (1watt/Kg). Pulmonary artery hypertension (at rest or after exercise) was frequently found in stage III, and less frequently in stage II. In stage I pulmonary artery mean pressure was between 15 and 20 mmHg in three patients (out of three). In one case (out of two) in stage 0 (admitted to hospital owing to exertional dyspnoea) right heart catheterisation showed pulmonary hypertension during exercise in spite of normal pulmonary function tests (including spirometry, DLCO, pulmonary scintigrafic and X-ray pattern also using 3X magnification radiology).


Assuntos
Hipertensão Pulmonar/etiologia , Sarcoidose/complicações , Adulto , Idoso , Cateterismo Cardíaco , Feminino , Hemodinâmica , Humanos , Hipertensão Pulmonar/diagnóstico , Masculino , Pessoa de Meia-Idade , Testes de Função Respiratória
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...